A systematic review was conducted to study the association between idiopathic inflammatory myopathies and incidence of cardiovascular outcomes.

In a systematic review and meta-analysis, researchers compared the incidence of Bell palsy among patients who received SARS-CoV-2 vaccination vs those who weren’t unvaccinated and those who received placebo.

Researchers conducted a systematic review to study factors and outcomes associated with sarcopenia in rheumatoid arthritis.

The US FDA approved a new drug for people who have a rare, inherited type of amyotrophic lateral sclerosis (ALS).

In a population-based study, researchers assessed COVID-19-related outcomes and vaccine uptake among adults with myasthenia gravis.

The FDA has approved Qalsody (tofersen) for the treatment of adults with ALS who have a mutation in the SOD1 gene.

The FDA granted Fast Track designation to AOC 1044 for treating Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping.

Researchers assessed whether impaired processing of emotional faces is associated with abnormal scan paths during visual exploration in patients with ALS without cognitive impairment.

Researchers sought to evaluate the safety and efficacy of avalglucosidase alfa among patients with late-onset Pompe disease during the COMET trial open-label extension period.

Researchers described the efficacy and safety results from the placebo-controlled phase of Study 041 on ataluren and change in ambulatory function in patients with Duchenne muscular dystrophy.

The FDA has granted Fast Track designation to RGX-202 for the treatment of Duchenne muscular dystrophy (DMD).

The trial met the criteria for futility and is being discontinued.

The FDA panel voted in favor of tofersen for accelerated approval in patients with superoxide dismutase 1 amyotrophic lateral sclerosis.

Using data from the BRIDGE-PMR trial, researchers assessed rates of glucocorticoid-free remission after rituximab infusion among patients with polymyalgia rheumatica.

Researchers compared the efficacy of intravenous cyclophosphamide and other immunosuppressants in the treatment of idiopathic inflammatory myopathy-related interstitial lung disease.

The Company is currently evaluating the efficacy and safety of taldefgrobep alfa in patients with SMA in the phase 3 RESILIENT study.

The researchers sought to understand the effect of complement 5 inhibition in the treatment of immune-mediated necrotizing myopathy.

Researchers explored experiences of enacted and felt stigma among patients with ALS or PMA and their caregivers.

Researchers sought to assess the diagnostic value of 18F-SynVesT-1 PET as a marker of ALS pathology and explore whether specific density signatures are present in ALS with different subtypes.

AOC 1020 is designed to reduce the expression of DUX4 mRNA and DUX4 protein in muscles.

Researchers sought to evaluate 3 muscle-enriched biomarkers in the serum of patients with BMD over 4 years-time and correlations with disease severity, disease progression, and dystrophin levels in BMD.

The BLA is supported by data from the phase 3 MycarinG study.

Authors recommend against clinical assessment alone when neuromuscular drugs are administered due to insensitivity of assessment

Magnitude of the association increased with the number of antiepileptic drugs prescribed

Only peak force fatigability, but not peak rate of force development, contributed to fatigue variance

SRP-9001 is an investigational gene transfer therapy designed to deliver a shortened, functional component of dystrophin to muscle tissue.

Greater decrease seen in nigrostriatal iron content with deferiprone, but more patients have symptom progression leading to initiation of dopaminergic therapy

Higher risk of cerebral palsy in offspring seen for severe injuries that resulted in hospitalization, delivery within one week from injury

Researchers sought to explore whether IVIG-C could effectively reduce the daily dose of corticosteroids in patients with MG.

In a prospective study, researchers evaluated the impact of nusinersen on upper extremity motor function in pediatric patients with SMA types 2 and 3.